AGMB

AgomAb Therapeutics NV
AGMB

15.55 USD
-0.06
0.38%
At close Updated Feb 10, 4:00 PM EST
Pre-market
After hours
14.13
-1.42
9.13%
1 day
-0.38%
5 days
5.78%
1 month
6.14%
3 months
6.14%
6 months
6.14%
Year to date
6.14%
1 year
6.14%
5 years
6.14%
10 years
6.14%
 

About: AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities with the aim of increasing efficacy while avoiding systemic toxicities in order to overcome the limitations of prior therapeutic approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Healthcare Biotechnology
–
Funds holding %
of 7,556 funds
Explore Fund Trends
–
Analysts bullish %
See Analyst Outlook
–
Positive news %
Check Journalist POV
Price charts implemented using Lightweight Charts™